



BIBLIOGRAPHY

- Adelstein, S., Baker, A., 2014. Making Sense of Inflammatory Markers. *The Royal College of Pathologists*, (June).
- Alagoz T, Buller R E, Berman M, Anderson B, Manetta A, DiSaia P, 1994. What is a normal CA125 level?. *Gynecol Oncol*, 53(1), 93-97.
- Amarenco, P., Cohen, A., Tzourjo, C., Bertrand, B., Hommel, M. et al., 1994. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. *New Engl J Med*, 331(22), 1474-1479.
- Aziz, M.F., 2009. Gynecological cancer in Indonesia. *J Gynecol Oncol*, 20(1), 8-10.
- Bast, R.C., Klug, T.L., Jenison, E., Niloff, J.M., Lazarus, H. et al., 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. *The New Engl J Med*, 309(15), 883-887.
- Bedell, S.E., Bush, B.T., 1985. Erythrocyte sedimentation rate. From folklore to facts. *Am J Med*, 76.
- Berek, J.S., Crum, C., Friedlander, M., 2012. Cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynecol Obstet*, 2.
- Cruickshank, A., Beetham, R., Holbrook, I., Watson, I., Wenham, P. et al., 2005. Spectrophotometry of cerebrospinal fluid in suspected subarachnoid hemorrhage. *BMJ (Clin Res ed.)*, 330(7483), 138.
- Diez-Silva, M., Dao, M., Han, J., Lim, C-T., Suresh, S., 2010. Shape and Biomechanical Characteristics of Human Red Blood Cells in Health and Disease. *MRS bulletin / Materials Research Society*, 35(5), 382-388.
- Eastham, R.D., 1954. The erythrocyte sedimentation rate and the plasma viscosity. *J Clin Path*, 7, 164-168.
- Felder, M., Kapur, A., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., Whelan, R.J., Patankar, M.S., 2016. MUC16 (CA125): tumor biomarker to cancer therapy , a work in progress. *Mol Cancer*, 16(1), 1-15.



Fluctuations and Shape Controlled by ATP-Induced Cytoskeletal Defects. *Biophys J*, 88(3), 1859-1874.

Honda, K., Ishiko, O., Tatsuta, I., Deguchi, M., Hirai, K., Nakata, S-I., Sumi, T., Yasui, T., Ogita, S., 1995. Anemia-inducing Substance from Plasma of Patients with Advanced Malignant Neoplasms, 3623-3628.

Longo, D.L., 2010. *Harrison's Hematology and Oncology*. 1st ed. United State: The McGraw-Hill Professional.

Lu, D-Y., Chen, X-L., Cao, J-Y., Li, Z., Xue, H-W., Luo, L-J., Xu, B., 1999. Comparison of some antineoplastic drugs on inhibiting thrombin catalizing fibrinogen clotting in vitro. *Chin Med J (Engl)*, 112.

Ma, Y., Qian, Y., Lv, W., 2007. The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma. *J Int Med Res*, 35, 678-684.

Mariani, G., Strober, W., Keiser, H., Waldmann, T.A., 1976. Pathophysiology of hypoalbuminemia associated with carcinoid tumor. *Cancer*, 38(2), 854-860.

McGarigal, K., 2011. *Analysis of Environmental Data Conceptual Foundations*.

McKenzie, S.B., Williams L, 2010. *Clinical Laboratory Hematology*. 2nd ed. United States:Pearson Education.

Medeiros, L.R., Rosa, D.D., da Rosa, M.I., Bozzetti, M.C., 2009. Accuracy of CA 125 in the diagnosis of ovarian tumours: a quantitative systemic review. *Eur J Obstet Gynecol Reprod Biol*, 142(2), 99-105.

Ngadikun, 2006. *Pattern of Alteration of Zeta Potential of Blood Cells (ZPBC) by Spectrophotometric Method in Hepatocellular Carcinoma Patients and Rats (Rattus norvegicus) Induced by Hepatocarcinogenic Agent [dissertation]*. Bandung: Universitas Padjajaran.

Ngadikun, 1998. *Pengukuran Laju Endap Darah ('Erythrocyte sedimentation Rate') Dengan Metode Spektrometri [Thesis]*. Jakarta: Universitas Indonesia.

O'Shannessy, D.J., Somers, E.B., Palmer, L.M., Thiel, R.P., Oberoi, P., Heath, R., Marcucci, L., 2013. Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to



disease stage and grade and comparison to CA125 and HE4. *J Ovarian Res*, 6(1), 29.

Ose, J. et al., 2015. Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition. *Inter J Cancer*, 136(2), 399-410.

Palumbo, J.S., Kombrinck, K.W., Drew, A.F., Grimes, T.F., Kiser, J.H. et al., 2000. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. *Blood*, 96(10), 3012-3309.

Polterauer, S., Grimm, C., Seebacher, V., Concin, N., Marth, C., Tomovski, C., Husslein, H., Leipold, H., Hefler-Frischmuth, K., Tempfer, C., Reinthaller, A., Hefler, L., 2009. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. *The oncologist*, 14(10), 979-985.

Rodak, B.F., Fritsma, G.A., Doig, K., 2007. *Hematology: Clinical Principles and Applications*. 3rd rev. ed. United States: Elsevier Health Sciences, 172.

Sharma, D., Brummel-Ziedins, K.E., Bouchard, B.A., Holmes, C.E., 2014. Platelets in Tumor Progression: A Host Factor That Offers Multiple Potential Targets in the Treatment of Cancer. *J Cell Physiol*, 229, 1005-1015.

Siegl, C., Hamminger, P., Jank, H., Ahting, U., Bader, B., Danek, A., Gregory, A., Hartig, M., Hayflick, S., Hermann, A., Prokisch, H., Sammler, E.M., Yapici, Z., Prohaska, R., Salzer, U., 2013. Alterations of Red Cell Membrane Properties in Neuroacanthocytosis. *PLoS ONE*, 8(10), 1-13.

Thabet, A., Somarouthu, B., Oliva, E., Gervais, D.A., Hahn, P.F. et al., 2014. Image-guided ovarian mass biopsy: efficacy and safety. *J Vasc Interv Radiol*, 25(12), 1922-1927.

Visintin, I., Feng, Z., Longton, G., Ward, D.C., Alvero, A.B., Lai, Y., Tenthorey, J., Leiser, A., Flores-Saab, R., Yu, H., Azori, M., Rutherford, T., Schwartz, P.E., Mor, G., 2008. Diagnostic markers for early detection of ovarian cancer. *Clin Cancer Res*, 14(4), 1065-1072.



of. *J Med (Cincinnati)*, 22(2), 214-218.

Welcsh, P.L., King, M.C., 2001. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. *Hum Mol Genet*, 10(7), 705-713.

Zijlstra, W.G., Buursma, A., Meeuwsen-van der Roest, W.P., 1991. Absorption spectra of human fetal and adult oxyhemoglobin, de-oxyhemoglobin, carboxyhemoglobin, and methemoglobin. *Clin Chem*, 37(9), 1633-1638.

Zwaveling, A., Soebhag, R., 1985. Testicular tumors in the Netherlands. *Cancer*, 55(7), 1612-1617.